BioSpace News Archive

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced that management will present a company update at the UBS Genomics 2.0 and Medtech Innovations Summit on Thursday, August 12, 2021 at 2:00pm Eastern Time.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced that the company will report financial results for the quarter ended June 30, 2021 on Thursday, August 5, 2021.

Seagen Inc. reported financial results for the second quarter and six months ended June 30, 2021.

Ligand Pharmaceuticals Incorporated reported financial results for the three and six months ended June 30, 2021 and provided an operating forecast and program updates.

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, August 4, 2021 at 4:30 p.m. ET.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2021.

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today reported financial results for the second quarter 2021 and provided general corporate and pipeline updates.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that management will be presenting at the UBS Genomics 2.0 and MedTech Innovations Summit on Wednesday, August 11, 2021, at 4:00 p.m. Pacific Time (PT)/7:00 p.m. Eastern Time (ET).

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., to the role of Chief Medical Officer, effective today.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its OCS™ Lung Solution for use in transplants using cold storage techniques.